Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cyclacel Pharmaceuticals ( (CYCC) ) has shared an announcement.
On June 20, 2025, Cyclacel Pharmaceuticals announced a securities purchase agreement with accredited investors for the sale of Series F Convertible Preferred Stock, raising $3 million. The funds will be used for general corporate purposes, and the transaction includes warrants for common stock. This financing is expected to extend Cyclacel’s cash runway into the third quarter of 2025, potentially impacting its operational stability and market positioning.
The most recent analyst rating on (CYCC) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Cyclacel Pharmaceuticals stock, see the CYCC Stock Forecast page.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines. Their strategy involves building a diversified biopharmaceutical business with a pipeline of novel drug candidates targeting oncology and hematology indications.
Average Trading Volume: 1,333,546
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.52M
Find detailed analytics on CYCC stock on TipRanks’ Stock Analysis page.